Investigating a pathway that may help treat breast cancer spreading to bones
CXCL5/CXCR2 axis as a therapeutic vulnerability of breast cancer metastasis to bone
This study is looking at how certain signals in the body help breast cancer spread to the bones, especially in women with estrogen receptor-positive breast cancer, and it will test new treatments to see if they can stop or slow down this spread.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Notre Dame NIH-funded |
| Lab location | 1 site (Notre Dame, United States) |
| Project ID | NIH-11088723 on NIH RePORTER |
What this research studies
This research focuses on understanding how certain signals in the body contribute to the spread of breast cancer to the bones, particularly in patients with estrogen receptor-positive breast cancer. It aims to explore the role of a specific chemokine, Cxcl5, and its receptor, CXCR2, in promoting this metastasis. The researchers will test new therapies, including CXCR2 inhibitors, either alone or in combination with existing treatments, to see if they can effectively prevent or reduce bone metastasis in breast cancer patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are women diagnosed with estrogen receptor-positive breast cancer who are at risk of or have developed bone metastasis.
Not a fit: Patients with non-estrogen receptor-positive breast cancer or those without bone metastasis may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options that specifically target and inhibit breast cancer metastasis to the bones, improving outcomes for patients.
How similar studies have performed: While the specific approach of targeting the CXCL5/CXCR2 axis is novel, similar strategies in targeting cancer metastasis have shown promise in other studies.
Where this research is happening
Notre Dame, United States
- University of Notre Dame — Notre Dame, United States (Active)
Researchers
- Principal investigator: Littlepage, Laurie E. — University of Notre Dame
- Study coordinator: Littlepage, Laurie E.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.